RxDoctor Payments Data

James Malone, DO

Family Medicine · Amarillo, TXNPI 1295920163

Payments from drug & device makers

$3,874in general payments, 2019–2025

Across 226 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$523
  • GSK$378
  • AbbVie$312
  • Novo Nordisk$274
  • Astellas Pharma US Inc$229
  • Pfizer$191
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$3,874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,874 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$138,433
Medicare patients
307
Services billed
4,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$95,044
JanuviaSitagliptin Phosphate80$67,100
JardianceEmpagliflozin33$48,999
OzempicSemaglutide57$48,022
FarxigaDapagliflozin Propanediol51$40,703
EliquisApixaban48$35,365
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,943
TrulicityDulaglutide33$31,039
TradjentaLinagliptin35$28,573
VascepaIcosapent Ethyl31$13,401
MyrbetriqMirabegron14$12,779
Breo ElliptaFluticasone/Vilanterol26$10,346
LinzessLinaclotide14$7,135
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,145
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$126$126,083113 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$165$83,16880 claims
MerckJanuvia$45$67,10080 claims
Novo NordiskOzempic$274$48,02257 claims
GSKTrelegy Ellipta, Breo Ellipta$378$45,28957 claims
AstraZenecaFarxiga$523$40,70351 claims
PfizerEliquis$191$35,36548 claims
Astellas Pharma US IncMyrbetriq$229$12,77914 claims
AbbVieLinzess, Synthroid$312$9,39245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →